Cantor Fitzgerald Reaffirms “Overweight” Rating for Taysha Gene Therapies (NASDAQ:TSHA)

Cantor Fitzgerald restated their overweight rating on shares of Taysha Gene Therapies (NASDAQ:TSHA – Free Report) in a report issued on Tuesday morning, Benzinga reports. They currently have a $7.00 target price on the stock. A number of other equities research analysts have also recently issued reports on the stock. Piper Sandler began coverage on […]

Leave a Reply

Your email address will not be published.

Previous post Ulta Beauty (NASDAQ:ULTA) PT Lowered to $525.00
Next post Insider Selling: Curtiss-Wright Co. (NYSE:CW) Director Sells 5,300 Shares of Stock